Sequel Med Tech collaborates with Abbott
By HME News Staff
Updated 10:09 AM CDT, Wed March 19, 2025
MANCHESTER, N.H. – Sequel Med Tech has announced that Abbott’s FreeStyle Libre 3 Plus sensor will be the first continuous glucose monitoring device to work with its twiist Automated Insulin Delivery (AID) System powered by Tidepool. The sensor will be compatible with twiist when the system is expected to launch in the second quarter of 2025. “We are thrilled to announce our collaboration with Abbott, integrating its world-leading FreeStyle Libre technology as our first CGM partner, marking a significant milestone as we bring our innovative AID system to market,” said Sequel CEO and Co-Founder Alan Lotvin, MD. “This collaboration highlights our commitment to making advanced diabetes management more accessible and flexible for people living with diabetes. Abbott’s FreeStyle Libre technology, known for its user-friendly design and broad accessibility, complements our innovative system.” Sequel says twiist is the first insulin delivery system that directly measures the volume of insulin delivered with every micro-dose. Its iiSure Technology also includes four checkpoints to provide accurate delivery, alerting users to blockages up to nine times faster than competing AID systems, the company says. Additionally, its Loop algorithm, based on the diabetes community driven Tidepool Loop, allows the system to automatically adjust basal insulin delivery based on real-time sensor readings and predicted glucose levels. twiist is cleared by the U.S. Food and Drug Administration for people ages six and up with Type 1 diabetes.
Comments